National Natural Science Foundation of China   Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4
Founded: Beijing China (1986)

Organization Overview

First Clinical Trial
2006
NCT00338793
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

National Natural Science Foundation of China

Active Ingredients

Drugs in Phase 4 Trials (20)

acetylsalicylic acid (aspirin) (4 trials)

alendronic acid (fosamax) (1 trial)

atorvastatin (lipitor) (2 trials)

cilostazol (pletal) (1 trial)

clopidogrel (plavix) (4 trials)

collagen (1 trial)

finerenone (KERENDIA) (1 trial)

isosorbide (isordil) (1 trial)

metoprolol (lopressor) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

olanzapine (zyprexa) (1 trial)

parecoxib (1 trial)

rosuvastatin (crestor) (1 trial)

sevoflurane (ultane) (1 trial)

spironolactone (aldactone) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

ticagrelor (brilinta) (2 trials)

trimetazidine (1 trial)

ursodeoxycholic acid (1 trial)

wen xin (1 trial)

Drugs in Phase 3 Trials (4)

bisoprolol (zebeta) (1 trial)

b multivitamins (1 trial)

pregabalin (lyrica) (1 trial)

rivaroxaban (xarelto) (1 trial)

Drugs in Phase 2 Trials (11)

allogeneic adipose derived mesenchymal stem cell (1 trial)

cyclosporine (sandimmune) (2 trials)

human fecal microbiota (Reybota) (1 trial)

losartan (cozaar) (1 trial)

nedaplatin (1 trial)

nicotinamide (1 trial)

pemetrexed (alimta) (2 trials)

temozolomide (temodar) (2 trials)

umbilical cord mesenchymal stem cells (2 trials)

vincristine (oncovin) (1 trial)

vitis vinifera (1 trial)

Drugs in Phase 1 Trials (4)

abatacept (orencia) (1 trial)

alteplase (Activase) (1 trial)

human placental derived stem cells (1 trial)

tirofiban (aggrastat) (1 trial)

Drugs in Other Trials (9)

betamethasone (celestone) (1 trial)

clarithromycin (biaxin) (1 trial)

fish oil (Omegavan) (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

linseed oil (2 trials)

prednisone (meticorten) (2 trials)

rituximab (rituxan) (1 trial)

triptorelin (Trelstar) (2 trials)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Angina Pectoris (Phase 4)

Angina, Unstable (Phase 4)

Atherosclerosis (Phase 2)

Brain Neoplasms (Phase 2)

Cardiomyopathies (Phase 3)

Cardiomyopathy, Dilated (Phase 3)

Central Nervous System Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Essential Hypertension (Phase 2)

Gastrointestinal Neoplasms (Phase 4)

Heart Diseases (Phase 4)

Hyperhomocysteinemia (Phase 3)

Hypertension (Phase 2)

Infarction (Phase 4)

Infarction, Anterior Cerebral Artery (Phase 4)

Insulin Resistance (Phase 4)

Lupus Erythematosus, Cutaneous (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lymphoma (Phase 2)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Duchenne (Phase 3)

Myocardial Ischemia (Phase 4)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Nervous System Neoplasms (Phase 2)

Neuralgia (Phase 3)

Osteogenesis Imperfecta (Phase 4)

Plaque, Atherosclerotic (Phase 2)

Schizophrenia (Phase 4)

Short Bowel Syndrome (Phase 4)

Syndrome (Phase 4)

Thalassemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 48